他汀类药物在治疗非酒精性脂肪肝病中的研究进展

被引:26
作者
陈思
赵金珍
胡晶
银孟卓
郭志刚
机构
[1] 南方医科大学南方医院惠侨医疗中心
基金
广东省自然科学基金;
关键词
他汀类药物; 非酒精性脂肪肝病; 心血管疾病; 肝脂肪变性; 肝纤维化;
D O I
暂无
中图分类号
R575.5 [肝代谢障碍];
学科分类号
100201 [内科学];
摘要
近年来,非酒精性脂肪肝病逐渐成为国内肝病相关死亡率的主要因素。非酒精性脂肪肝病的发病机制主要与代谢综合征相关,其危险因素主要包括肥胖、2型糖尿病、脂代谢异常等,这些危险因素与心血管疾病密切相关,心血管疾病死亡率也成为非酒精性脂肪肝病首要的死亡原因。他汀类药物是最主要的降脂药物,有证据表明,非酒精性脂肪肝病患者使用他汀类药物降脂治疗不仅能有效降低肝脏转氨酶水平,降低心血管疾病病死率,而且能有效减轻肝脏脂肪变性程度,同时可能对延缓肝脏纤维化有一定的疗效。
引用
收藏
页码:297 / 303
页数:7
相关论文
共 29 条
[1]
Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome [J].
Kargiotis, Konstantinos ;
Athyros, Vasilios G. ;
Giouleme, Olga ;
Katsiki, Niki ;
Katsiki, Evangelia ;
Anagnostis, Panagiotis ;
Boutari, Chrysoula ;
Doumas, Michael ;
Karagiannis, Asterios ;
Mikhailidis, Dimitri P. .
WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (25) :7860-7868
[2]
他汀治疗对非酒精性脂肪肝患者动脉弹性的影响 [J].
刘怀昌 ;
吴华锋 ;
张继平 .
中国动脉硬化杂志, 2013, 21 (10) :920-922
[3]
Statins for Improving Myocardial Perfusion in Patients With Nonalcoholic Fatty Liver Disease Undergoing Percutaneous Coronary Intervention [J].
Athyros, Vasilios G. ;
Tziomalos, Konstantinos ;
Karagiannis, Asterios .
AMERICAN JOURNAL OF CARDIOLOGY, 2016, 117 (02) :311-312
[4]
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2 [J].
Jacobson, Terry A. ;
Maki, Kevin C. ;
Orringer, Carl E. ;
Jones, Peter H. ;
Kris-Etherton, Penny ;
Sikand, Geeta ;
La Forge, Ralph ;
Daniels, Stephen R. ;
Wilson, Don P. ;
Morris, Pamela B. ;
Wild, Robert A. ;
Grundy, Scott M. ;
Daviglus, Martha ;
Ferdinand, Keith C. ;
Vijayaraghavan, Krishnaswami ;
Deedwania, Prakash C. ;
Aberg, Judith A. ;
Liao, Katherine P. ;
McKenney, James M. ;
Ross, Joyce L. ;
Braun, Lynne T. ;
Ito, Matthew K. ;
Bays, Harold E. ;
Brown, W. Virgil .
JOURNAL OF CLINICAL LIPIDOLOGY, 2015, 9 (06) :S1-S122
[5]
Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels.[J].Matti J. Tikkanen;Rana Fayyad;Ole Faergeman;Anders G. Olsson;Chuan-Chuan Wun;Rachel Laskey;John J. Kastelein;Ingar Holme;Terje R. Pedersen.International Journal of Cardiology.2013,
[6]
Rosuvastatin ameliorates high-fat and high-cholesterol diet-induced nonalcoholic steatohepatitis in rats [J].
Okada, Yoshihisa ;
Yamaguchi, Kanji ;
Nakajima, Tomoki ;
Nishikawa, Taichiroh ;
Jo, Masayasu ;
Mitsumoto, Yasuhide ;
Kimura, Hiroyuki ;
Nishimura, Takeshi ;
Tochiki, Nozomi ;
Yasui, Kohichiroh ;
Mitsuyoshi, Hironori ;
Minami, Masahito ;
Kagawa, Keizo ;
Okanoue, Takeshi ;
Itoh, Yoshito .
LIVER INTERNATIONAL, 2013, 33 (02) :301-311
[7]
Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property.[J].Hideyuki Hyogo;Sho-ichi Yamagishi;Sayaka Maeda;Yuki Kimura;Tomokazu Ishitobi;Kazuaki Chayama.Digestive and Liver Disease.2011, 6
[8]
The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology [J].
Chalasani, Naga ;
Younossi, Zobair ;
Lavine, Joel E. ;
Diehl, Anna Mae ;
Brunt, Elizabeth M. ;
Cusi, Kenneth ;
Charlton, Michael ;
Sanyal, Arun J. .
GASTROENTEROLOGY, 2012, 142 (07) :1592-1609
[9]
The diagnosis and management of non‐alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases; American College of Gastroenterology; and the American Gastroenterological Association.[J].Naga Chalasani;Zobair Younossi;Joel E. Lavine;Anna Mae Diehl;Elizabeth M. Brunt;Kenneth Cusi;Michael Charlton;Arun J. Sanyal.Hepatology.2012, 6
[10]
Efficacy of rosuvastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study [J].
Nakahara, Takashi ;
Hyogo, Hideyuki ;
Kimura, Yuki ;
Ishitobi, Tomokazu ;
Arihiro, Koji ;
Aikata, Hiroshi ;
Takahashi, Shoichi ;
Chayama, Kazuaki .
HEPATOLOGY RESEARCH, 2012, 42 (11) :1065-1072